Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.39 |
| ▸ | CCND1 | P24385 | 9/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.39 |
| ▸ | CCND3 | P30281 | 9/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034851 | 0.93 | CDK4 (0.39) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041256 | 0.90 | CDK4 (0.37) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15035066 | 0.83 | CDK4 (0.35) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041753 | 0.82 | CDK4 (0.40) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15034869 | 0.81 | CDK4 (0.41) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041641 | 0.79 | CDK4 (0.37) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041221 | 0.78 | CDK4 (0.39) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041764 | 0.78 | PRKCZ (0.39) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041613 | 0.75 | CDK4 (0.36) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041612 | 0.74 | CDK4 (0.43) | CDK4CCND1CDK2CCNA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | CDK4 408/4885CCND1 3984/4885CDK2 104/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CDK2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.